Cost Savings Observed With Docetaxel Versus Abiraterone Acetate for Prostate Cancer

According to a study presented at the 2018 ASCO Annual Meeting, docetaxel and abiraterone acetate have similar survival benefits for patients with castration-resistant prostate cancer, but docetaxel resulted in more than $200,000 in cost savings. This is the first study to address the cost-effectiveness of these two agents. 

Using a Markov cohort model, the researchers assessed data from the CHAARTED and LATITUDE studies. The addition of docetaxel or abiraterone acetate to androgen deprivation therapy improved progression-free survival quality-adjusted life years by 0.26 and 0.54, respectively, and increased the treatment cost by $12,185 and $208,684, respectively. 

Source: ASCO